ADJUVANT PUBLICATIONS & ABSTRACTS
Adjuvant data
Evidence / Adjuvant
Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome
PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. AUTHORS: Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van't Veer L.J. SUMMARY: MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with Read More
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards ABSTRACT: It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor α (ERα), Read More
Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience
PUBLICATION: Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. AUTHORS: Torrisi R., Garcia-Etienne C.A., Losurdo A., Morenghi E., Di Tommaso L., Gatzemeier W., Sagona A., Fernandes B., Rossetti C., Eboli M., Rubino A., Barbieri E., Andreoli C., Orefice S., Gandini C., Rota S., Zuradelli M., Masci G., Santoro A., Read More
MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer
PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. AUTHORS: Grant K.A., Apffelstaedt J.P., Wright C.A., Myburgh E., Pienaar R., De Klerk M., Kotze M.J. SUMMARY: The 70-gene profile classifies approximately 40% of early-stage breast cancer patients as low-risk compared with 15% using conventional criteria. In comparison, more than Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retèl Read More
A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study
PUBLICATION: Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub 2013 Mar 4. AUTHORS: Drukker C.A., Bueno-de-Mesquita J.M., Retèl V.P., van Harten W.H., van Tinteren H., Wesseling J., Roumen R.M., Knauer M., van't Veer L.J., Sonke G.S., Rutgers E.J., van de Vijver M.J., Linn S.C. SUMMARY: A prospective community based Read More
The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase
PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742–2749. AUTHORS: Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso Read More
